STOCK TITAN

Psyched Wellness Stock Price, News & Analysis

PSYCF OTC Link

Company Description

Psyched Wellness Ltd. (OTCQB: PSYCF) is a Canadian-based health supplements and life sciences company focused on the production and distribution of mushroom-derived consumer packaged goods. The company is repeatedly described in its disclosures as a health supplements company and a life sciences company specializing in products derived from the Amanita muscaria mushroom, using its proprietary extract known as AME-1.

According to multiple corporate updates, Psyched Wellness is dedicated to researching, producing and distributing mushroom-derived products and associated consumer packaged goods. The company’s stated objective is to create premium Amanita muscaria-derived and mushroom-derived products with the potential to become a North American brand in the emerging functional food category. Its activities include the development of Amanita muscaria-derived water-based extracts, teas and capsules that are being designed around three health objectives: promoting stress relief, supporting relaxation and assisting with restful sleeping.

Business focus and product development

Psyched Wellness describes itself as focused on the production and distribution of health and wellness products derived from the Amanita muscaria mushroom. A central element of its business is AME-1, which the company refers to as its proprietary extract of Amanita muscaria. Corporate communications state that Psyched Wellness is working to bring AME-1-based dietary supplements and related consumer products to market.

The company has disclosed the development and sale of several branded products built around AME-1. Its flagship product is Calm, which is associated with AME-1 and is produced in formats such as tinctures. Psyched Wellness has also announced Calmer, described as a new product offering that delivers twice the potency of Calm, and notes that it has enhanced the flavour profile of Calm in different bottle sizes while maintaining potency and consumer experience. In addition, the company has discussed the development of a dietary supplement shot, referred to in updates as a 4 oz shot and later as Santa, and has indicated that this format is being beta tested with target consumers.

Further product development efforts include Amanita muscaria gummies for sale in the United States, branded as Fly (Agaric). Psyched Wellness states that these gummies use AME-1 in their formulation and describes them as Amanita muscaria watermelon gummies intended for online and select retail availability. Across its communications, the company consistently notes that it is in the process of developing a line of Amanita muscaria-derived water-based extracts, teas and capsules aligned with stress relief, relaxation and sleep-related objectives.

Scientific and regulatory work around AME-1

Psyched Wellness emphasizes scientific and regulatory work related to AME-1. The company has disclosed that it engaged a licensed contract research organization to complete a GAP analysis and path to market for its flagship product as a health supplement. It has also announced that it is conducting a Genotoxicity Study on AME-1, including tests such as the AMES test, in vitro TK-MLA assay and micronucleus assay, and has characterized progress as promising in its updates.

The company reports that a third-party laboratory conducted a six-month accelerated stability study on AME-1, with results indicating that AME-1 maintains muscimol content up to 18 months and shows no microbial growth under accelerated conditions. Based on this, Psyched Wellness has stated that Calm will carry an 18‑month shelf life. The company has also voluntarily submitted a New Dietary Ingredient Notification (NDIN) to the U.S. Food and Drug Administration for AME-1, describing the submission as including historical food use information and voluntary toxicology and safety studies of AME-1. In its own statements, Psyched Wellness indicates that it views itself as compliant with applicable U.S. dietary supplement law and emphasizes its focus on transparency and regulatory compliance as it brings additional AME-1 products to market.

Manufacturing, distribution and route-to-market

Corporate communications describe Psyched Wellness as focused on both direct-to-consumer online sales and brick-and-mortar retail distribution. The company notes that it uses a third-party manufacturing facility in the United States to produce AME-1 and Calm and has disclosed a supply chain disruption at that facility, stating that it would temporarily suspend online sales to prioritize inventory for retail partners and subscribers while working to secure additional contract manufacturers.

Psyched Wellness reports that it is growing its route-to-market partnerships across Canada and the United States and repeatedly invites interested distributors and retailers to contact the company regarding Calm and other products. It has highlighted relationships with specialty retailers, naming Erewhon, Central Markets, Good Earth Markets, Market of Choice and Harmons as retail partners that have signed on to sell Calm. The company also notes that it has engaged UNFI, described as a large wholesale distributor of health and specialty food across the United States and Canada, to support distribution for certain retail partnerships.

In its own statements, Psyched Wellness characterizes itself as focusing on working with a select group of specialty retailers that offer high-quality products and positions AME-1-based offerings as Amanita muscaria-derived products that are legal for human consumption in the United States. The company also references efforts to increase direct-to-consumer sales via its online store while adding key retailers in the wellness space.

Corporate profile and positioning

Across multiple news releases, Psyched Wellness describes itself as a Canadian-based health supplements company and a life sciences company focused on mushroom-derived products. It highlights its dedication to the distribution of mushroom-derived products and associated consumer packaged goods and to the research and production of consumer packaged goods derived from AME-1. The company’s stated objective is to create premium Amanita muscaria-derived products with potential in the functional food category, and it frequently references the emerging nature of this category in North America.

Psyched Wellness also discloses collaborations and advisory relationships, including work with Zerkalo LLC on brand development and new dietary supplement products using AME-1. It has mentioned a U.S. subsidiary, AME Wellness Inc., involved in pilot runs of new dietary supplement shots. The company notes that it has submitted a scaled-up extraction process patent application to the U.S. Patent and Trademark Office, with that application described as pending in the United States and Canada.

Risk considerations and forward-looking statements

In its cautionary statements, Psyched Wellness outlines risks and uncertainties associated with its business. These include the potential inability to continue as a going concern, possible governmental or regulatory actions affecting operations, competition in markets that include psychedelics and functional mushrooms, and risks related to the safety and purity of Amanita muscaria consumption and extracts, as well as the possibility that there may be no benefit from such consumption. The company emphasizes that forward-looking statements in its releases are based on assumptions about continued regulatory approval of its activities, the ability to develop mushroom-derived products and associated consumer packaged goods, and the continued growth of the company.

How Psyched Wellness stock is classified

On Stock Titan, Psyched Wellness Ltd. (PSYCF) is associated with the Pharmaceutical Preparation Manufacturing industry within the broader Manufacturing sector. At the same time, the company’s own descriptions emphasize its role as a health supplements and life sciences business centered on Amanita muscaria-derived consumer products, AME-1 and related formulations such as Calm, Calmer, Santa and Fly (Agaric) gummies.

Stock Performance

$0.0107
0.00%
0.00
Last updated: February 20, 2026 at 15:59
-36.69%
Performance 1 year

SEC Filings

No SEC filings available for Psyched Wellness.

Financial Highlights

Revenue (TTM)
Net Income (TTM)
Operating Cash Flow

Upcoming Events

Short Interest History

Last 12 Months
Loading short interest data...

Short interest in Psyched Wellness (PSYCF) currently stands at 112.0 thousand shares, up 1000.0% from the previous reporting period, representing 0.1% of the float. Over the past 12 months, short interest has increased by 5423.8%. This relatively low short interest suggests limited bearish sentiment.

Days to Cover History

Last 12 Months
Loading days to cover data...

Days to cover for Psyched Wellness (PSYCF) currently stands at 1.0 days. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The ratio has shown significant volatility over the period, ranging from 1.0 to 2.2 days.

Frequently Asked Questions

What is the current stock price of Psyched Wellness (PSYCF)?

The current stock price of Psyched Wellness (PSYCF) is $0.0107 as of February 20, 2026.

What is the market cap of Psyched Wellness (PSYCF)?

The market cap of Psyched Wellness (PSYCF) is approximately 4.3M. Learn more about what market capitalization means .

What does Psyched Wellness Ltd. do?

Psyched Wellness Ltd. describes itself as a Canadian-based health supplements and life sciences company focused on the production and distribution of mushroom-derived products and associated consumer packaged goods. Its business centers on health and wellness products derived from the Amanita muscaria mushroom, using its proprietary extract AME-1.

What is AME-1 at Psyched Wellness?

AME-1 is Psyched Wellness Ltd.’s proprietary extract of the Amanita muscaria mushroom. The company states that it uses AME-1 as the basis for its dietary supplements and other consumer packaged goods, and it has conducted scientific studies and regulatory submissions focused on AME-1, including genotoxicity and stability studies and a New Dietary Ingredient Notification to the U.S. FDA.

Which products has Psyched Wellness highlighted in its disclosures?

Psyched Wellness has referenced several AME-1-based products, including its flagship product Calm, the higher-potency product Calmer, a dietary supplement shot branded as Santa, and Amanita muscaria gummies called Fly (Agaric). The company also notes that it is in the process of developing Amanita muscaria-derived water-based extracts, teas and capsules aligned with stress relief, relaxation and sleep-related objectives.

How does Psyched Wellness distribute its products?

The company reports that it uses both direct-to-consumer online sales and brick-and-mortar retail distribution. Psyched Wellness highlights partnerships with specialty retailers such as Erewhon, Central Markets, Good Earth Markets, Market of Choice and Harmons, and notes that it has engaged UNFI to support distribution. It also states that it is growing route-to-market partnerships across Canada and the United States.

What scientific studies has Psyched Wellness conducted on AME-1?

Psyched Wellness has disclosed a Genotoxicity Study on AME-1, including the AMES test, in vitro TK-MLA assay and the micronucleus assay. It also engaged a third-party laboratory to perform a six-month accelerated stability study, reporting that AME-1 maintained muscimol content up to 18 months with no microbial growth under accelerated conditions. These studies support its product shelf life and safety assessments.

How is Psyched Wellness approaching regulatory requirements in the United States?

The company states that it voluntarily submitted a New Dietary Ingredient Notification to the U.S. Food and Drug Administration for AME-1. Psyched Wellness explains that the submission included historical food use information and safety studies, and it indicates that under U.S. law the NDIN requirement is a notification process. The company says it views itself as compliant with the Federal Food, Drug, and Cosmetic Act and emphasizes transparency and regulatory compliance as it brings AME-1 products to market.

What risks does Psyched Wellness identify in its forward-looking statements?

In its cautionary statements, Psyched Wellness notes risks such as the potential inability to continue as a going concern, possible governmental or regulatory actions affecting its operations, competition in markets that include psychedelics and functional mushrooms, and risks related to the safety and purity of Amanita muscaria consumption and extracts. It also acknowledges the possibility that there may be no benefit from Amanita muscaria consumption.

How does Psyched Wellness describe its position in the functional food category?

Psyched Wellness states that its objective is to create premium Amanita muscaria-derived and mushroom-derived products that have the potential to become a North American brand in the emerging functional food category. This positioning is based on its focus on mushroom-derived consumer packaged goods aimed at stress relief, relaxation and sleep-related health objectives.

What manufacturing and supply chain details has Psyched Wellness disclosed?

The company has disclosed that a third-party contractor operates its sole manufacturing facility in the United States used to produce AME-1 and Calm. It reported a supply chain disruption at that facility and indicated that it would temporarily suspend online sales while using existing inventory to support retail partners and subscribers, and that it was working to secure additional co-manufacturers.

Does Psyched Wellness engage in patent-related activities?

Yes. Psyched Wellness has announced that it submitted a scaled-up extraction process patent application to the U.S. Patent and Trademark Office, identified as a U.S. application number in its disclosure, and stated that the application is pending in both the United States and Canada.